Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.

Journal of pediatric endocrinology & metabolism : JPEM - 1 Mar 2003

Brunelli V L, Russo G, Bertelloni S, Gargantini L, Balducci R, Chiesa L, Livieri C, De Sanctis C, Einaudi S, Virdis R, Saggese G, Chiumello G

Abstract excerpt

OBJECTIVE: To investigate the influence of target height (TH), gender, phenotype, glucocorticoid formulation and age at onset of treatment on final height (FH) in patients with 21-hydroxylase deficiency (21OHD). PATIENTS: Clinical data of 93 patients--46 simple virilizing (SV), 35 salt-wasting (SW) and 12 late onset (LO)--were collected in six pediatric endocrinology units in Italy. RESULTS: FH and TH were always...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Hyperplasia, Congenital
Share to Body Height

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to SDS gene

Share to Glucocorticoids

Share to Phenotype

Share to Sex Characteristics

Source

Identifiers

PMID: 12729404

Genes

SDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.PMID 12729404Read ↗

Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.Semantic proximity Read ↗

CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency.Semantic proximity Read ↗

Clinical, biochemical and genetic features with nonclassical 21-hydroxylase deficiency and final height.Semantic proximity Read ↗

Growth and Treatment in Congenital Adrenal Hyperplasia: An Observational Study from Diagnosis to Final Height.Semantic proximity Read ↗

Congenital adrenal hyperplasia clinical characteristics and genotype in newborn, childhood and adolescence.Semantic proximity Read ↗

Adult height of subjects with nonclassical 21-hydroxylase deficiency.Semantic proximity Read ↗

Newborn screening-detected 21-hydroxylase deficiency: growth pattern is not associated with the genotype.Semantic proximity Read ↗

Follow-Up of 68 Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency: Relevance of Genotype for ManagementSemantic proximity Read ↗

Long term outcome in adult males with classic congenital adrenal hyperplasia.Semantic proximity Read ↗

Genotype-phenotype association in congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children.Semantic proximity Read ↗

Pregnancy outcomes in women with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Semantic proximity Read ↗

Female pseudohermaphroditism and inefficient peak bone mass in an untreated subject affected by 21-hydroxylase congenital adrenal hyperplasia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.